Johnson & Johnson (JNJ)
160.13
+0.27
(+0.17%)
USD |
NYSE |
Nov 01, 16:00
160.23
+0.10
(+0.06%)
After-Hours: 20:00
Johnson & Johnson Enterprise Value: 400.99B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 400.99B |
| October 31, 2024 | 400.34B |
| October 30, 2024 | 402.14B |
| October 29, 2024 | 400.89B |
| October 28, 2024 | 404.53B |
| October 25, 2024 | 402.79B |
| October 24, 2024 | 409.51B |
| October 23, 2024 | 414.78B |
| October 22, 2024 | 408.98B |
| October 21, 2024 | 407.49B |
| October 18, 2024 | 413.00B |
| October 17, 2024 | 411.44B |
| October 16, 2024 | 410.98B |
| October 15, 2024 | 410.49B |
| October 14, 2024 | 404.47B |
| October 11, 2024 | 404.14B |
| October 10, 2024 | 401.85B |
| October 09, 2024 | 402.19B |
| October 08, 2024 | 399.88B |
| October 07, 2024 | 399.49B |
| October 04, 2024 | 401.32B |
| October 03, 2024 | 401.83B |
| October 02, 2024 | 403.44B |
| October 01, 2024 | 405.41B |
| September 30, 2024 | 405.58B |
| Date | Value |
|---|---|
| September 27, 2024 | 404.55B |
| September 26, 2024 | 404.52B |
| September 25, 2024 | 402.62B |
| September 24, 2024 | 407.87B |
| September 23, 2024 | 408.93B |
| September 20, 2024 | 411.19B |
| September 19, 2024 | 412.78B |
| September 18, 2024 | 415.98B |
| September 17, 2024 | 418.19B |
| September 16, 2024 | 418.00B |
| September 13, 2024 | 414.46B |
| September 12, 2024 | 412.34B |
| September 11, 2024 | 412.78B |
| September 10, 2024 | 418.94B |
| September 09, 2024 | 417.09B |
| September 06, 2024 | 411.72B |
| September 05, 2024 | 413.19B |
| September 04, 2024 | 418.89B |
| September 03, 2024 | 418.41B |
| August 30, 2024 | 415.28B |
| August 29, 2024 | 411.36B |
| August 28, 2024 | 410.61B |
| August 27, 2024 | 408.28B |
| August 26, 2024 | 412.27B |
| August 23, 2024 | 411.12B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
301.41B
Minimum
Mar 23 2020
492.23B
Maximum
Apr 25 2022
419.71B
Average
422.02B
Median
Oct 13 2021
Enterprise Value Benchmarks
| Amgen Inc | 222.98B |
| Eli Lilly and Co | 805.11B |
| Merck & Co Inc | 284.75B |
| Pfizer Inc | 221.03B |
| AbbVie Inc | 417.06B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 2.694B |
| Revenue (Quarterly) | 22.47B |
| Total Expenses (Quarterly) | 17.19B |
| EPS Diluted (Quarterly) | 1.11 |
| Gross Profit Margin (Quarterly) | 69.01% |
| Profit Margin (Quarterly) | 11.99% |
| Earnings Yield | 3.78% |
| Operating Earnings Yield | 5.87% |
| Normalized Earnings Yield | 5.326 |